Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab + TCS in severe atopic dermatitis (ECZTRA 7)
NCT03761537Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Dec 2018
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Tralokinumab + TCS with Placebo + TCS (2 arms). Primary endpoint: At Least 75% Reduction in Eczema Area and Severity Index From Week 0 to Week 16. Started Dec 2018; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03761537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761537.